March 30, 2022 -- Cabotegravir and rilpivirine (Cabenuva), an HIV treatment co-developed by ViiV Healthcare and Janssen, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV-1 in virologically suppressed adolescents who are 12 years of age or older.
The treatment contains ViiV Healthcare's cabotegravir extended-release injectable suspension in a single-dose vial and rilpivirine extended-release injectable suspension in a single-dose vial, a product of Janssen Sciences Ireland Unlimited Company, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Cabenuva is a once-monthly or every-two-months injectable treatment. The FDA approval is based on the First Long-Acting Injectable Regimen week 124 results, which indicated efficacy, tolerability, pharmacokinetics, and safety of Cabenuva, Janssen said in a release.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
